Introduction
The burden of disease is an increasingly important factor in health policy (Murray and Lopez, 1996a) . It is reasonable that more resources should be allocated to diseases that are common than to rare diseases and, likewise, more should be allocated to diseases that highly impact on the lives of people. Similar arguments apply to teaching and research. However, the burden of disease varies tremendously in different parts of the world. In developing countries perinatal disorders, malnutrition, infectious diseases and violence are still dominating, whilst this role is taken by the non-communicable diseases in more wealthy countries (Murray and Lopez, 1996a) . With the increasing unity in Europe, exemplified by the recent decision to admit 10 new countries into the union, the European aspects of research, education and health policy will grow in importance. Rational policies in these areas require solid data about the burden of disease within the territory of Europe and such European data have not been available until the publication of the 1990 World Health Organisation (WHO), Harvard, World Bank study of the Global Burden of Disease (GBD) (Murray and Lopez, 1996b, 1997a,b,c,d) . Improved data have been generated in the GBD 2000 study of which version 2 is now available .
In the present paper we focus on brain diseases, a relatively new term that includes all diseases traditionally viewed as neurological, psychiatric and neurosurgical. In other words, the diseases located in the central or peripheral nervous system whether caused primarily by environmental or by psychological factors. Data on these diseases for Europe are scattered in several places in the GBD 2000 document because the WHO groups diseases according to aetiology when possible. Therefore, the list of neuropsychiatric diseases in WHO terminology does not include all diseases located in the brain . We have extracted the data on the burden of brain diseases (neuropsychiatric diseases and others) as defined in the International Classification of Diseases (ICD) 10th edition (WHO, 1992-94) and its neurological adaptation (ICD10NA) (WHO, 1997) for the territory of Europe. The burden of these diseases is calculated in percentage of the total burden of all diseases in Europe.
By presenting the data on brain diseases in Europe in an easily accessible and comprehensible form, an increased understanding of the huge burden of brain diseases may be achieved, thereby, promoting initiatives to augment prevention, treatment, research and teaching of the brain and its diseases.
Methods
The methods used in the GBD 2000 study have been extensively described elsewhere by those responsible for the study (Murray and Lopez, 1996b, 1997a,b,c,d; Mathers et al., 2002) . Some general features of the methodology that must be understood in order to read the present paper are explained herein.
Years of life lost (YLL) is the number of years of healthy life lost because of a disease. In other words, the number of years that a disease shortens normal life expectancy.
Years lived with disability (YLD), which can be considered years lost because of disability, is the most difficult component of the burden of disease analysis. Various methods have been developed to reconcile often fragmented and partial estimates available from different studies. A specific software tool, DisMod, has been developed to assist in the development of internally consistent estimates (Murray and Lopez, 1997d) . YLDs are the disability component of DALYs. The basic formula for calculating YLD is:
where I is the number of incident cases in the reference period, DW is the disability weight (in the range 0-1) and L is the average duration of disability (measured in years).
The full formula with discounting and non-uniform age weights is given elsewhere (Murray, 1996; Mathers et al., 2001) . Consistent and meaningful YLD estimates depend on a clear definition of the condition under consideration in terms of case or episode, and severity level or disease stage. It is then necessary to ensure that the disability weight and the population incidence or prevalence data relate to the same case definition. Data on disease incidence, disease duration, age of onset and distribution by severity class which are required to estimate YLD must be disaggregated by age and sex. These in turn require estimates of incidence, remission, case-fatality rates or relative risks, by age and sex.
At present, the YLD estimates for version 2 of the GBD 2000 are still based largely on the GBD 1990 disability weights (Murray et al., 2002) . Groups of experts from all regions of the world have estimated the severity of 22 indicator disabling conditions such as blindness, depression and painful conditions from 0 (perfect health) to 1 (equal to death). These weights were then grouped into seven classes. Each participant was asked two versions of the question. One about extending life for people in a given health state versus extending life for healthy people and the second about giving health back to people in a given health state versus extending life for healthy people. Groups of eight to twelve participants have worked together discussing their choices with their peers. They have been allowed to revise their initial choices. Once the 22 indicator conditions have been weighted, the participants assigned weights to the remaining conditions. In nine exercises, there was close agreement about the disability weights. The GBD study evaluated the importance of variability of the disability weights and concluded that the influence was minor. The important factors were the underlying epidemiological data (Murray and Lopez, 1996c) .
Disability adjusted life years is one of the main summary measure of population's health. It is calculated by the formula:
Thus it includes years of life lost because of premature death and years lived with disability.
Results
All data in the present study on the burden of brain diseases have been extracted from WHO documents WHO, 2001) . It is reported from three different regions of Europe. The definition of the regions and a list of countries included are given in Table 1 . Results from all over Europe generated by adding figures for strata A, B and C are also given. In Table 2 is given the size of the European population according to age and sex in the different regions. Table 3 gives a list of disorders included in this study with their ICD10 codes. Many important brain diseases, that could not be included in this survey, are listed at the end of the table.
Other diseases which are clearly located in the brain but are coded elsewhere and without specific data on the brain (brain neoplasms) could not be included. Some conditions are included in the present study with a percentage of their burden because they also have consequences outside the brain (congenital abnormalities and trauma). Neurological complications to extracerebral disease such as diabetic neuropathy are not included in this paper.
In Table 4 YLL caused by brain diseases are given and in Table 5 YLD caused by brain diseases for the three strata of Europe and for all of Europe. For comparison we also bring the total data for YLL and YLD caused by all diseases together in the territory of Europe. The relative importance of brain diseases compared with all diseases in terms of lost lives and years lost because of disability are shown in Figs 1 and 2. The key parameter in the estimation of the burden of disease, DALYs, caused by brain diseases in Europe are given in Table 6 for the three strata and for all of Europe. The DALYs caused by all diseases together are given for comparison. A better impression of the relative importance of brain diseases can be found in Fig. 3 , which shows the number of DALYs caused by brain diseases in percentage of total DALYs caused by all diseases in the A, B and C regions and in all of Europe. It appears that brain diseases account for 35% of total DALYs caused by all diseases in Europe. Table 7 presents the top 10 diseases causing DALYs in Europe. Number 2 is stroke, number 3 is unipolar diorders, number 4 is alcohol use disorder and number 5 is dementia. In addition, self-inflicted injuries and trauma are on the list so that in total six of the top 10 most burdensome disorders are brain diseases or at least have a very significant brain involvement.
Discussion
This is the first paper to focus exclusively on the burden of brain diseases in Europe. Data from WHO study of the global burden of disease (GBD 2000) is presented Leonardi, 2003 those working in the European Commission, in the European Parliament or in a nation, region or institution of Europe.
The spectrum of brain diseases
A starting point for defining the brain disease spectrum is ICD10 (WHO, 1992-94) and its neurological adaptation ICD10NA (WHO, 1997) . In the global burden of disease study (Murray and Lopez, 1996b, 1997a,b,c,d; Mathers et al., 2002) it has only been possible to include diseases for which reasonably good statistics are available and many brain diseases could not be included. Dementia is clearly an organic disease of the brain and has been included as a neuropsychiatric condition in ICD10 and so also in the present study. However, it is most often cared for by general practitioners and geriatricians. We fully realize that it is not possible for neurology and psychiatry to care for all people with dementia. This should be carried out in close collaboration between general practice and several specialties. However, for the purpose of the present paper, it is reasonable to include the figures for dementia because, indisputably, it is located in the brain.
As the WHO classification is primarily aetiological, several diseases are coded according to their aetiology and not to the psychiatric or neurological sections, even if they are clearly located to the central or the WHO 2001) and therefore are also not included in the present results. Developmental disorders are very prevalent and represent a considerable burden of disease but insufficient data have precluded their inclusions here. Brain neoplasms are also not included because they were not specified in the source document . Finally, the central and peripheral nervous systems are often affected as a consequence of general medical conditions. For example, one of the most burdensome complications of diabetes is diabetic neuropathy. Anoxic brain damage is a severe complication of cardiac arrest, chemotherapy causes polyneuropathy, heart diseases and other somatic illness often cause depression and so on. All these complications have not been included because their burden is accounted under the primary medical condition. The opposite, that brain diseases cause systemic complications that are counted under the brain disease is rare. Thus, the figures we have presented here are minimum figures for the burden of brain diseases.
The burden of brain diseases
Until at present, there has been no study of the overall burden of brain diseases in the territory of Europe. However, such figures are badly needed for the planning of European research-, educational-and health policies. The WHO data using DALYs represent a unique resource. The study spans all of Europe, not just the European union, it uses the same methodology in all countries and it combines the impact of early death with the impact of years lived with disability. DALYs is a summary measure of health that is independent of individual disease characteristics, avoids the controversies between direct and indirect health costs and can be used in all societies regardless of their stage of development. Therefore, it is well suited for comparing the burden of different groups of diseases in different regions (Murray, 1996; Mathers et al., 2001) . The figures for the burden of brain diseases in Europe as extracted in the present study from WHO's figures are surprisingly high: 35% of the total burden of all diseases. If all relevant diseases, sequelae and complications could be included it might be even higher. The burden of brain diseases will increase in the future because of the ageing population in Europe. In the first global burden of disease study, projections for the year 2020 were made (Murray and Lopez, 1997d) . They showed a marked increase in the burden of non-communicable diseases in general and of the brain diseases in particular. Thus, the present study has uncovered not only a huge burden to European society but also a growing problem that can undermine the future European economy unless forceful action is taken to prevent it. In this respect, it is extremely unfortunate that the recent European Health Report from the WHO Regional Office for Europe (WHO, 2002) hardly mentions this problem.
Conclusions and recommendations
Considering that 35% of the burden of all diseases is caused by brain diseases, these diseases have received relatively little attention. Despite the proven value of stroke units, for example, the great majority of stroke victims are still admitted to general medical wards. Little effort is spent on the prevention of this second most burdensome disease in Europe compared with the prevention of cardiac diseases. Unipolar depression, the third in line, is often undiagnosed or untreated. Dementia, the fourth most burdensome of all diseases in Europe, accounts for the majority of nursing home residents but most of these persons have never received a diagnosis. The heavy burden of migraine and of nonmigraine headaches has not yet led to prevention efforts or to specialized headache centres in most countries. To amend the situation, resource allocation should be analysed in detail. Is there enough teaching of neuroscience and of brain diseases at medical schools and nursing schools? Is a reasonable proportion of research funds allocated to basic and clinical neuroscience? Are the efforts in prevention, primary care and hospital treatment sufficient? The huge burden of brain diseases requires a response to all these questions. Society must also address the fact that the burden of brain diseases will further increase in the next 10-20 years. We recommend that one-third of the curriculum at medical schools should be devoted to the brain and its diseases, that one-third of life sciences research funding should be devoted to the brain and its diseases and that a greater fraction of health care expenditure should be allocated to alleviate the burden of brain diseases.
